GR3029853T3 - Diazabicyclic neurokinin antagonists - Google Patents

Diazabicyclic neurokinin antagonists

Info

Publication number
GR3029853T3
GR3029853T3 GR990400941T GR990400941T GR3029853T3 GR 3029853 T3 GR3029853 T3 GR 3029853T3 GR 990400941 T GR990400941 T GR 990400941T GR 990400941 T GR990400941 T GR 990400941T GR 3029853 T3 GR3029853 T3 GR 3029853T3
Authority
GR
Greece
Prior art keywords
diazabicyclic
neurokinin antagonists
compounds
formula
disorders
Prior art date
Application number
GR990400941T
Other languages
English (en)
Inventor
Harry R Howard Jr
Kevin D Shenk
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of GR3029853T3 publication Critical patent/GR3029853T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
GR990400941T 1993-12-29 1999-04-05 Diazabicyclic neurokinin antagonists GR3029853T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17503493A 1993-12-29 1993-12-29
PCT/IB1994/000352 WO1995018129A1 (en) 1993-12-29 1994-11-14 Diazabicyclic neurokinin antagonists

Publications (1)

Publication Number Publication Date
GR3029853T3 true GR3029853T3 (en) 1999-07-30

Family

ID=22638565

Family Applications (1)

Application Number Title Priority Date Filing Date
GR990400941T GR3029853T3 (en) 1993-12-29 1999-04-05 Diazabicyclic neurokinin antagonists

Country Status (26)

Country Link
US (2) US5854239A (el)
EP (1) EP0737194B1 (el)
JP (1) JP2895630B2 (el)
KR (1) KR100197454B1 (el)
CN (1) CN1046515C (el)
AT (1) ATE177099T1 (el)
AU (1) AU699465B2 (el)
BR (1) BR9408450A (el)
CA (1) CA2180263C (el)
CO (1) CO4230019A1 (el)
CZ (1) CZ282567B6 (el)
DE (1) DE69416869T2 (el)
DK (1) DK0737194T3 (el)
ES (1) ES2127946T3 (el)
FI (1) FI108296B (el)
GR (1) GR3029853T3 (el)
HU (1) HUT74682A (el)
IL (1) IL112118A (el)
NO (1) NO305600B1 (el)
NZ (1) NZ274915A (el)
PE (1) PE49395A1 (el)
PL (1) PL179435B1 (el)
RU (1) RU2124014C1 (el)
TW (1) TW369526B (el)
WO (1) WO1995018129A1 (el)
ZA (1) ZA9410339B (el)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69416869T2 (de) * 1993-12-29 1999-07-01 Pfizer Diazabicyclische neurokinin antagonisten
FR2786770B1 (fr) * 1998-12-04 2001-01-19 Synthelabo Derives de 1,4-diazabicyclo[3.2.2.]nonane, leur preparation et leur application en therapeutique
NZ523310A (en) * 2000-06-12 2005-07-29 Univ Rochester Tachykinin receptor antagonist to block receptors NK1, NK2, and NK3 and treat symptoms of hormonal variation
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
SE0003795D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Pharmaceutically useful compounds
FR2825705B1 (fr) * 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2844273B1 (fr) 2002-09-05 2008-04-04 Aventis Pharma Sa Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens.
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
FR2848210B1 (fr) * 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
KR101412339B1 (ko) 2004-07-15 2014-06-25 알바니 몰레큘라 리써치, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를차단하기 위한 용도
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
WO2006135783A2 (en) * 2005-06-10 2006-12-21 Wisconsin Alumni Research Foundation Compositions and methods for modulating angiogenesis
US7956050B2 (en) 2005-07-15 2011-06-07 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
EP1940842B1 (en) 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2008039327A2 (en) 2006-09-22 2008-04-03 Merck & Co., Inc. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
TWI404532B (zh) * 2006-11-02 2013-08-11 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
PL2336120T3 (pl) 2007-01-10 2014-12-31 Msd Italia Srl Kombinacje zawierające indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy) (PARP)
US8106086B2 (en) 2007-04-02 2012-01-31 Msd K.K. Indoledione derivative
CA2690191C (en) 2007-06-27 2015-07-28 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
KR101800610B1 (ko) 2008-01-18 2017-11-23 머크 샤프 앤드 돔 코포레이션 베타­락타마제 억제제
WO2009111354A2 (en) 2008-03-03 2009-09-11 Tiger Pharmatech Tyrosine kinase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
KR101830447B1 (ko) 2009-05-12 2018-02-20 알바니 몰레큘라 리써치, 인크. 7-(［1,2,4］트리아졸로［1,5-α］피리딘-6-일)-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로이소퀴놀린 및 이의 용도
US9034899B2 (en) 2009-05-12 2015-05-19 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
WO2010132487A1 (en) 2009-05-12 2010-11-18 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
FR2951171A1 (fr) * 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
PE20121172A1 (es) 2009-10-14 2012-09-05 Merck Sharp & Dohme Piperidinas sustituidas con actividad en la hdm2
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
CA2805265A1 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
CA2807307C (en) 2010-08-17 2021-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP2632472B1 (en) 2010-10-29 2017-12-13 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
SG191320A1 (en) * 2010-12-22 2013-07-31 Meiji Seika Pharma Co Ltd Optically-active diazabicyclooctane derivative and method for manufacturing same
IN2013MN02170A (el) 2011-04-21 2015-06-12 Piramal Entpr Ltd
PT2748165T (pt) * 2011-08-27 2016-12-28 Wockhardt Ltd Derivados de 1,6-diazabiciclo[3,2,1]octano-7-ona e sua utilização no tratamento de infeções bacterianas
CA2845108C (en) * 2011-08-30 2015-06-16 Wockhardt Limited 1,6-diazabicyclo[3,2,1]octan-7-one derivatives and their use in the treatment of bacterial infections
BR112014003476A2 (pt) * 2011-09-13 2017-03-01 Wockhardt Ltd compostos contendo nitrogênio e seu uso
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
EP2844261B1 (en) 2012-05-02 2018-10-17 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
ES2758507T3 (es) * 2012-05-30 2020-05-05 Meiji Seika Pharma Co Ltd Nuevo inhibidor de B-lactamasa y método para producir el mismo
WO2014052563A2 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
MX363243B (es) 2012-11-28 2019-03-14 Merck Sharp & Dohme Composiciones para tratar cáncer y usos de dichas composiciones.
BR112015013611A2 (pt) 2012-12-20 2017-11-14 Merck Sharp & Dohme composto, e, composição farmacêutica
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
BR112015021186A2 (pt) * 2013-03-08 2017-07-18 Wockhardt Ltd processo para a preparação de (2s,5r)-7-oxo-6-sulfóxi-2-[((3r)-pirrolidina-3-carbonil)-hidrazino carbonil]-1,6-diaza-biciclo[3.2.1]octano
BR112015021332B1 (pt) * 2013-03-08 2020-06-30 Wockhardt Limited sal de sódio de ácido (2s, 5r)-6-benzilóxi-7-oxo-1,6-diaza-biciclo [3.2.1] octano-2-carboxílico e sua preparação
NZ711327A (en) * 2013-03-08 2016-06-24 Wockhardt Ltd A process for preparation of (2s, 5r)-7-oxo-6-sulphooxy-2-[((3r)-piperidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo [3.2.1]- octane
JP6182621B2 (ja) * 2013-03-08 2017-08-16 ウォックハート リミテッド （２ｓ，５ｒ）−硫酸モノ−｛［（４−アミノピペリジン−４−イル）カルボニル］−７−オキソ−１，６−ジアザ−ビシクロ［３．２．１］オクタ−６−イル｝エステルを調製するための方法
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
MY193210A (en) * 2013-09-24 2022-09-26 Meiji Seika Pharma Co Ltd Process for producing diazabicyclooctane derivative
DK3221313T3 (en) 2014-11-17 2019-04-08 Entasis Therapeutics Ltd COMBINATION THERAPY FOR TREATING INFECTIONS WITH RESISTANT BACTERIA
MX2017012545A (es) * 2015-04-03 2018-09-28 Mutabilis Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
LT3512851T (lt) 2016-09-16 2022-10-25 Entasis Therapeutics Limited Beta-laktamazės inhibitorių junginiai
US11046694B2 (en) 2017-05-08 2021-06-29 Entasis Therapeutics, Inc. Compounds and methods for treating bacterial infections
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
CN108610313B (zh) * 2018-06-08 2022-03-04 三峡大学 一种酶抑制剂及其应用
US20210277009A1 (en) 2018-08-07 2021-09-09 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3494923A (en) * 1965-05-28 1970-02-10 Sterling Drug Inc 1,2,3,4,5,8-hexahydro-1,5-methanobenzo (f)(1,4)diazocine
DK0573522T3 (da) * 1991-03-01 1995-03-06 Pfizer 1-Azabicyclo(3,2,2)nonan-3-aminderivater
DE69416869T2 (de) * 1993-12-29 1999-07-01 Pfizer Diazabicyclische neurokinin antagonisten

Also Published As

Publication number Publication date
PE49395A1 (es) 1996-01-06
EP0737194A1 (en) 1996-10-16
NO962742L (no) 1996-06-28
CN1139434A (zh) 1997-01-01
TW369526B (en) 1999-09-11
IL112118A (en) 1998-10-30
CN1046515C (zh) 1999-11-17
US5854239A (en) 1998-12-29
IL112118A0 (en) 1995-03-15
ES2127946T3 (es) 1999-05-01
FI946140A (fi) 1995-06-30
DK0737194T3 (da) 1999-09-27
AU8002194A (en) 1995-07-17
BR9408450A (pt) 1997-08-05
JPH09500904A (ja) 1997-01-28
CZ282567B6 (cs) 1997-08-13
RU2124014C1 (ru) 1998-12-27
FI108296B (fi) 2001-12-31
CZ188696A3 (en) 1996-10-16
AU699465B2 (en) 1998-12-03
DE69416869D1 (de) 1999-04-08
PL179435B1 (pl) 2000-09-29
HUT74682A (en) 1997-01-28
CO4230019A1 (es) 1995-10-19
JP2895630B2 (ja) 1999-05-24
US6110919A (en) 2000-08-29
NO305600B1 (no) 1999-06-28
HU9601790D0 (en) 1996-09-30
NZ274915A (en) 1997-11-24
PL315193A1 (en) 1996-10-14
DE69416869T2 (de) 1999-07-01
FI946140A0 (fi) 1994-12-28
WO1995018129A1 (en) 1995-07-06
ATE177099T1 (de) 1999-03-15
KR100197454B1 (ko) 1999-06-15
NO962742D0 (no) 1996-06-28
ZA9410339B (en) 1996-06-28
CA2180263C (en) 2000-05-16
EP0737194B1 (en) 1999-03-03

Similar Documents

Publication Publication Date Title
IL112118A0 (en) Diazabicyclic neurokinin antagonists
MY121294A (en) Novel hexanoic acid derivatives.
HU9303515D0 (en) Pyrrolo-pyrimidines
CA2150123A1 (en) Aminomethylene substituted non-aromatic heterocycles
IL108769A0 (en) Spirocyclic piperidine derivatives
WO1993000330A3 (en) Azanorbornane derivatives
MY105438A (en) 3-aminopiperidine derivatives and related nitrogen containing heterocycles.
CA2141048A1 (en) Substituted benzylamino nitrogen containing non-aromatic heterocycles
ES2149888T3 (es) 3-(3,4-dioxifenil)-pirrolidinas como inhibidores de la fosfodiesterasa de tipo iv para el tratamiento de enfermedades inflamatorias.
HU9700113D0 (en) Substituted pyrimidine compounds and their use
DK0765320T3 (da) Benzimidazolonderivater med central dopaminerg aktivitet
MX9700959A (es) Derivados de becimidazol que tienen actividad dopaminergica.
BG105549A (en) Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system